RxDoctor Payments Data

Timothy Gammons, DO

Addiction Medicine · Sterling Heights, MINPI 1730163023

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,800 of the $9,357 with a category attached, or 72.7%. 23 manufacturers reported payments, led by Orexo US, Inc. at 38.4% of the total. Reporting peaked in 2019 at $6,882 and has fallen 96.5% since, to $238 in 2025. Among addiction medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,357in general payments, 2019–2025

Across 129 payments — averaging $72.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$4K
  • Sandoz$3K
  • Indivior Inc.$841
  • AbbVie$759
  • Pfizer$186
  • Gilead$142
  • plus $553 from 17 others

What the payments were for

  • Consulting fees$6,80073%
  • Travel & lodging$3794%
  • Food & beverage$2,17823%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,357 in reported general payments places this provider in the 95th percentile of 62 addiction medicine providers in Michigan.

See all addiction medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$4,932
Medicare patients
27
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl90$13,897
SuboxoneBuprenorphine Hcl/Naloxone Hcl20$9,626
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$153
Gabapentin11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$841$9,62620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 addiction medicine providers in Michigan.

Other addiction medicine in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →